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ttp://dx.doi.org/10.1016/j.jmoldx.2014.12.003The use of droplet digital PCR (ddPCR) for low-level DNA mutation detection in cancer, prenatal
diagnosis, and infectious diseases is growing rapidly. However, although ddPCR has been implemented
successfully for detection of rare mutations at pre-determined positions, no ddPCR adaptation for
mutation scanning exists. Yet, frequently, clinically relevant mutations reside on multiple sequence
positions in tumor suppressor genes or complex hotspot mutations in oncogenes. Here, we describe a
combination of coampliﬁcation at lower denaturation temperature PCR (COLD-PCR) with ddPCR that
enables digital mutation scanning within approximately 50-bp sections of a target amplicon. Two FAM/
HEX-labeled hydrolysis probes matching the wild-type sequence are used during ddPCR. The ratio of
FAM/HEX-positive droplets is constant when wild-type amplicons are ampliﬁed but deviates when
mutations anywhere under the FAM or HEX probes are present. To enhance the change in FAM/HEX ratio,
we employed COLD-PCR cycling conditions that enrich mutation-containing amplicons anywhere on the
sequence. We validated COLD-ddPCR on multiple mutations in TP53 and in EGFR using serial mutation
dilutions and cell-free circulating DNA samples, and demonstrate detection down to approximately
0.2% to 1.2% mutation abundance. COLD-ddPCR enables a simple, rapid, and robust two-ﬂuorophore
detection method for the identiﬁcation of multiple mutations during ddPCR and potentially can
identify unknown DNA variants present in the target sequence. (J Mol Diagn 2015, 17: 284e292;
http://dx.doi.org/10.1016/j.jmoldx.2014.12.003)Supported by National Cancer Institute grant numbers R21CA-155615
(G.M.M.), R21CA-175542 (G.M.M.), and R01CA135257 (P.A.J.).
The contents of this paper do not necessarily represent the ofﬁcial views
of the National Cancer Institute or the NIH.
Disclosures: COLD-PCR is a technology owned by the Dana-Farber
Cancer Institute and has been commercially licensed.In the era of personalized medicine, mutation detection
methods that target mutations known to inﬂuence therapy
response or clinical outcome are of great interest. Although
real-time PCR methodologies have been described and are
widely used for detecting mutations in clinical samples,1e4
interest in digital PCR5 is rising in view of the unique
aspects of the technology and the emergence of commercial
droplet digital PCR (ddPCR) platforms.5e8 ddPCR has been
implemented in a variety of ﬁelds such as cancer biomarker and
viral load detection, fetal screening, or library quantiﬁcation for
next-generation sequencing.9 One of the most common ddPCR
applications is in the detection of known DNA variants present
within a large excess of wild-type DNA, for instance in DNA
from heterogeneous samples that harbor subclonal populations
of mutated tumor cells.10stigative Pathology
.In ddPCR, the ampliﬁcation reaction is compartmentalized
into microscopic emulsion-based droplets containing at most a
few target molecules per droplet. By segregating the interro-
gated sample, the effect of in-droplet target competition is
reduced, which translates into increased assay discrimination
and facile determination of wild-type versus mutant status.11
However, as currently applied, ddPCR can only be used to
detect mutations at known sequence positions. ddPCR
Table 1 Summary of Cell Lines Used
Target region Cell line Mutation (nt) Mutation (aa)
EGFR exon 20 H1975 c.2369C>T p.T790M
TP53 exon 8 SW480 c.818G>A p.R273H
DU-145 c.820G>T p.V274F
MDA-MB-231 c.839G>A p.R280K
HCC2218 c.847C>T p.R283C
aa, amino acid; nt, nucleotide.
COLD-ddPCR Enhanced Mutation Scanningincorporates two reporter probes, one mutant-speciﬁc and
one wild-type, because of the requirement to account
for PCR-ampliﬁcation variability among droplets. This
approach, by design, allows only the detection of previously
known mutations. In cancer, tumor suppressor genes such
as TP53 harbor mutations that are scattered throughout the
gene as opposed to oncogenes that usually carry mutations
located in speciﬁc hotspots.12 Although mutation scanning
methods based on amplicon ﬂuorescent melting analysis
following real-time PCR have been developed,13e16 moni-
toring ﬂuorescent melting within individual droplets during
ddPCR is not available at this time. Accordingly, a ddPCR
approach that could be implemented in a mutation scanning
format is desirable.
Here, we demonstrate that incorporation of coampliﬁcation
at lower denaturation temperature PCR (COLD-PCR),17e21
within the ddPCR workﬂow in conjunction with two ﬂuo-
rescently labeled probes matching the wild-type amplicon,
provides a simple and robust method for mutation scanning of
target amplicons. COLD-PCR suppresses wild-type sequences
and enables preferential ampliﬁcation of mutation-containing
droplets, for any mutation along the amplicon.21,22 Detecting
changes to the ratio of COLD-PCReenhanced signals caused
by mutations anywhere within the probed region enables
mutation scanning with high selectivity. This novel enhanced
ratio of signal-based mutation scanning COLD-ddPCR
enables a rapid method for the detection of mutations
during ddPCR without prior knowledge of the speciﬁc
DNA variant present in the target sequence. We demon-
strate in this paper the application of COLD-ddPCR to the
detection of multiple mutations present in TP53 exon 8,Table 2 List of Clinical Samples Used for Validation Purposes
Target region Sample name Type Tumor/origin
TP53 exon 8 CT20 gDNA Colorectal cancer
FC39e4 cfDNA Esophageal cancer
EGFR exon 20 PT-04e09 cfDNA Lung adenocarcinoma
PT-21 cfDNA Lung adenocarcinoma
PT-04e11 cfDNA Lung adenocarcinoma
PT-10e06 cfDNA Lung adenocarcinoma
PT-07e16 cfDNA Lung adenocarcinoma
PT-10e33 cfDNA Lung adenocarcinoma
PT-04e17 cfDNA Lung adenocarcinoma
Circulating cell-free tumor DNA samples (cfDNA).
*Mutation frequencies were estimated by previous analysis or conventional dig
aa, amino acid; DNA, genomic DNA; nt, nucleotide.
The Journal of Molecular Diagnostics - jmd.amjpathol.orgas well as for the T790M resistance mutation in EGFR
exon 20 in DNA from mutated cell lines and cell-free
circulating DNA (cfDNA) from clinical cancer samples.Materials and Methods
Cell Lines and Clinical Samples
Missense mutations in several positions of the TP53 exon 8
and mutation p.T790M in EGFR exon 20 were assessed in this
study. Human genomic DNA from cancer cell lines DU-145
(ATCC HTB-81D), HCC2218 (ATCC CRL-2343), and
MDA-MB-231 (ATCC HTB-26D) was purchased from
ATCC (Manassas, VA). Genomic DNA from commercial cell
lines SW480 (ATCC no. CCL-228) and H1975 (ATCC no.
CRL-5908) was extracted using the DNeasy Blood and Tissue
kit (Qiagen, Valencia, CA) following the manufacturer’s
protocol (Table 1). Human genomic DNA (Promega, Madi-
son, WI) was used as wild-type control DNA and for creating
dilutions of gradually decreasing mutation abundances. All
experiments were replicated at least three independent times
for assessing the reproducibility of the results.
To evaluate the efﬁcacy of this assay in characterizing
specimens from different origins, we analyzed a colorectal
tumor sample, known to harbor a G>A (p.R273H) missense
mutation present at a low frequency (approximately 1%).
This mutation had been previously identiﬁed and validated
using different methods [COLD-PCR sequencing, dena-
turing high-pressure liquid chromatography, restriction
endonuclease-mediated selective PCR, and differential
strand separation at critical temperature (Tc)
16,23]. We also
evaluated cfDNA isolated from patients with lung adeno-
carcinomas at different stages of disease progression and
treatment, and a cfDNA sample from an esophageal cancer
case. Mutations in these cfDNA samples had been previ-
ously identiﬁed using a ddPCR allele-speciﬁc approach
with hydrolysis probes speciﬁc either to the wild-type or the
mutant allele.24 Samples were obtained from patients after
informed consent and Dana Farber-Cancer Institute Insti-
tutional Review Board approval (Table 2).Mutation (nt) Mutation (aa) Estimated frequency*
c.818G>A p.R273H w1%
c.847C>T p.R283C w5%
c.2369C>T p.T790M w0.1%
c.2369C>T p.T790M Wild type
c.2369C>T p.T790M w2.1%
c.2369C>T p.T790M w0.43%
c.2369C>T p.T790M w2.03%
c.2369C>T p.T790M w0.38%
c.2369C>T p.T790M w4.08%
ital PCR using allele-speciﬁc probes.
285
Table 3 List of Primers and Probes Sequences Used in This Study
Target region PCR round Primer and probe sequences Size (bp)
TP53 exon 8 Genomic DNA pre-amplification F: 50-GCTTCTCTTTTCCTATCCTG-30 167
R: 50-CTTACCTCGCTTAGTGCT-30
Digital PCR F: 50-TGGTAATCTACTGGGACG-30 87
R: 50-CGGAGATTCTCTTCCTCT-30
Hydrolysis probes 50-FAM-TGGGAGAGACCGGCGCA-BHQ_1-30*
50-HEX-TTTGAGGTGCGTGTTTGTGCC-BHQ_1-30*
EGFR exon 20 Genomic DNA pre-amplification F: 50-GCTGGGCATCTGCCTCACCTCCACCGTGCAACT-30 91
R: 50-GTCTTTGTGTTCCCGGACATAG-30
Digital PCR F: 50-GCTGGGCATCTGCCTCA-30 67
R: 50-CAGGAGGCAGCCGAAGG-30
Hydrolysis probes 50-FAM-ATGAGTTGCACGGTGGA-BHQ_1-30*
50-HEX-CTCATCACGCAGCTCATG-BHQ_1-30*
50-FAM-CTCATCATGCAGCTCATG-BHQ_1-30y
50-HEX-CTCATCACGCAGCTCATG-BHQ_1-30y
*These hydrolysis probes had sequences complementary to the wild-type allele.
yHydrolysis probes speciﬁc to the mutant (FAM) or wild-type (HEX) allele used for precise quantiﬁcation of mutational abundances.
F, forward; R, reverse.
Castellanos-Rizaldos et alGenomic and cfDNA Pre-Ampliﬁcation Step
Gene-speciﬁc primers were used to pre-amplify selected
targets from genomic or cfDNA (approximately 20 ng and
approximately 10 ng, respectively) before performing
ddPCR experiments. Twenty cycles of pre-ampliﬁcation of
EGFR exon 20 were done using the GoTaq Flexi DNA
polymerase system (Promega) and 0.2 mmol/L forward and
reverse primers. Inconsistent with previous studies, the
forward primer was engineered to encompass the A/G
single nucleotide polymorphism present within this
amplicon to generate a uniform template for downstream
analysis.25,26 The initial 30 cycles of pre-ampliﬁcation of
TP53 exon 8 were conducted using the Phusion polymer-
ase system (New England Biolabs, Ipswich, MA) and 0.2
mmol/L forward and reverse primers (Tables 3 and 4).
Ampliﬁed DNAwas then diluted and used as a template for
ddPCR experiments using nested primers (Table 3).
ddPCR Using Ratio of Signals from Wild-Type Probes
To apply COLD-ddPCR approach, two TaqMan hydrolysis
probes (FAM and HEX labeled, respectively) were designed
to match the wild-type sequence and to bind to different
regions on the target amplicon (Figure 1).
Conventional ddPCR Cycling Conditions
Conventional ddPCR reactions were performed following
the manufacturer’s indications (Bio-Rad Laboratories, Her-
cules CA). Ampliﬁcations were performed in a 20-mL volume
containing 2 ddPCR supermix for probes (Bio-Rad Labo-
ratories), 900 nmol/L forward and reverse primers (synthe-
sized by Integrated DNA Technologies, Coralville, IA), 250
nmol/L FAM and HEX probes (Integrated DNA Technolo-
gies), and pre-ampliﬁed DNA template (using 1:4000 ﬁnal
dilution for the EGFR exon 20 experiments and 1:100,000 for286the TP53 exon 8) (Table 3). We started from a pre-ampliﬁed
template, given the nature (very low number of target
copies) of the samples used for the validation stage (cfDNA).
Droplets were then generated using the DG8 droplet generator
cartridges by mixing the aqueous phase with 70 mL of droplet
generation oil (DG; Bio-Rad Laboratories). Samples were
transferred to a 96-well reaction plate and then sealed using the
PX1 PCR plate sealer (Bio-Rad Laboratories) for 10 seconds
at 180C before thermal cycling. Cycling conditions for
conventional ddPCR are summarized in Table 4.
COLD-ddPCR Principles and Cycling Conditions
In its simplest form, COLD-PCR (fast-COLD-PCR22)
is performed by replacing the conventional denaturation
temperature during the PCR cycling by a lower denatur-
ation temperature. This results in a preferential ampliﬁca-
tion of mutations that decrease the melting temperature
of the amplicon (G:C>A:T and G:C>T:A, or melting
temperatureedecreasing insertion-deletions). These mu-
tation types comprise the majority (70% to 95%) of somatic
mutations reported in breast, lung, gastric, colorectal, renal,
ovarian, glioma, andmelanoma cancers, as well as germline
polymorphisms.27 In conventional ddPCR, once the DNA
is compartmentalized, PCR ampliﬁcation occurs simul-
taneously in every droplet. By contrast, COLD-ddPCR
ampliﬁcation takes place at a denaturation temperature
lower than that of the denaturation temperature of the
wild-type amplicon. As a result, ampliﬁcation occurs
preferentially within those droplets where the mutant
allele is present, resulting in a mutant-biased ampliﬁca-
tion (Figure 2).
To determine the optimal critical denaturation tempera-
ture (Tc) for the COLD-ddPCR reactions, a gradient of Tc
temperatures was tested using the Eppendorf Mastercycler
(Eppendorf, Hamburg, Germany). Series of wild-type and
3% to 5% mutation-containing samples were used in ddPCRjmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 4 Cycling Conditions Used
Target region PCR round Cycling conditions
TP53 exon 8 Genomic DNA pre-amplification Initial denaturation 98C for 30 seconds
Thermocycling: 30 cycles 98C for 10 seconds
58C for 20 seconds
72C for 10 seconds
Conventional Digital PCR Initial denaturation 95C for 10 minutes
Thermocycling: 40 cycles 94C for 30 seconds
58C for 60 seconds
Hold 98C for 10 minutes
Digital COLD-PCR Initial denaturation 95C for 10 minutes
Thermocycling: 5 cycles 94C for 30 seconds
58C for 60 seconds
Thermocycling: 40 cycles 78C (Tc) for 30 seconds
58C for 60 seconds
Hold 98C for 10 minutes
EGFR exon 20 Genomic DNA pre-amplification Initial denaturation 95C for 120 seconds
Thermocycling: 20 cycles 95C for 15 seconds
55C for 30 seconds
72C for 30 seconds
72C for 60 seconds
Conventional Digital PCR Initial denaturation 95C for 10 minutes
Thermocycling: 40 cycles 94C for 30 seconds
52C for 60 seconds
Hold 98C for 10 minutes
Digital COLD-PCR Initial denaturation 95C for 10 minutes
Thermocycling: 5 cycles 94C for 30 seconds
52C for 60 seconds
Thermocycling: 35 cycles 79.9C (Tc) for 30 seconds
52C for 60 seconds
Hold 98C for 10 minutes
COLD-PCR, coampliﬁcation at lower denaturation temperature PCR.
COLD-ddPCR Enhanced Mutation Scanningreactions using the temperature gradient feature of the thermal
cycler. We ﬁrst tested a broad temperature window and then
narrowed it to a 1C temperature window to ﬁnd a suitable Tc
(Supplemental Figures S1 and S2). As in bulk-solution
COLD-PCR, the Tc chosen was the lowest temperature that
generates substantial inhibition, yet reproducible ampliﬁca-
tion, for the wild-type sample.28 At this temperature, the FAM/
HEX differences between wild-type and mutant samples were
maximized.
Despite the wild-type inhibition, ampliﬁcation still occurs
in a fraction of wild-type DNAecontaining droplets, hence
providing positive signals in both HEX and FAM channels.
The threshold in the QuantaSoft software (Bio-Rad Labora-
tories) is set such that for wild-type control samples, FAM/
HEXZ 1. The same threshold was then applied to all inter-
rogated samples. Samples with the FAM/HEX ratio deviating
substantially from1 (P< 0.01) are consideredmutant. ddPCR
reactions were then analyzed and processed using the droplet
reader and the QuantaSoft software version 1.3.2.0.
Allele-Speciﬁc ddPCR and Calculation of Fractional
Abundance of Mutation
To validate mutational abundances in the cfDNA samples,
two hydrolysis (TaqMan) probes, binding to the sameThe Journal of Molecular Diagnostics - jmd.amjpathol.orgDNA region, were designed for allele-speciﬁc ddPCR.
Reactions were run under conventional PCR cycling
conditions per manufacturer recommendations: FAM-
labeled, complementary to the mutant allele, and HEX-
labeled, complementary to the wild-type allele. Hydrolysis
probes (Table 3) were synthesized by Integrated DNA
Technologies.
Calculation of absolute number of positive events for a
given channel (FAM or HEX), and the ratio and the frac-
tional abundance of mutation for each sample were per-
formed by the QuantaSoft software. The ratio was
calculated as the number of copies per microliter obtained in
the FAM channel (A), divided by copies per microliter in
the HEX channel (B): A/B. The fractional abundance of
mutant allele was obtained by dividing the number of copies
per microliter of mutant allele (FAM channel) by the total
copies per microliter of wild-type allele (HEX) plus mutant
(FAM): [A/(AþB)]. The determination of number of target
copies per droplet (number of copies of target molecule)
was adjusted by the software to ﬁt a Poisson distribution
model with a 95% conﬁdence level. The t-test was con-
ducted to evaluate the statistical signiﬁcance of the FAM/
HEX ratio differences between wild-type and mutant
alleles. Results with a two-tailed P value below 0.01 were
considered signiﬁcant.287
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Figure 2 Diagram summarizes the principles of fast coampliﬁcation at
lower denaturation temperatureedroplet digital PCR (fast-COLD-ddPCR).
Both mutant and wild-type alleles are compartmentalized into thousands of
droplets before the thermal cycling step. In conventional ddPCR, both wild-
type and mutant amplicons coamplify in different compartments. If fast-
COLD-ddPCR is implemented during the thermal cycling inhibition of the
wild-type amplicon, preferential ampliﬁcation of mutation-containing
droplets occurs. amp., ampliﬁcation; mut, mutant; WT, wild type.
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B
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Figure 1 A: Signal generation during enhanced ratio of signals for
mutation scanning coampliﬁcation at lower denaturation temperaturee
droplet digital PCR (COLD-ddPCR). The system incorporates two hydrolysis/
reporter probes that are complementary to the wild-type sequence. When the
interrogated DNA region does not contain mismatches that may prevent the
reporter probes to hybridize, both probes emit similar signals, translated
into a 1:1 FAM/HEX ratio. B: If there is a mutation (G:C>A:T or G:C>T:A)
present under one of the probes, the mismatch will affect the probe-target
DNA binding, reducing the overall ﬂuorescence of that particular probe,
producing a >1 or <1 FAM/HEX ratio. On the graph representing Taqman
probes and DNA templates, the circles labeled on the left side of each probe
are FAM (grey) or HEX (black). The circles labeled on the right side of each
probe are quenchers (BHQ-1). The suns represent the release of FAM or HEX
from the probe during COLD-ddPCR.
Castellanos-Rizaldos et alResults
COLD-ddPCR Method for EGFR p.T790M Mutation
During COLD-ddPCR, the presence of a mutation-
generated mismatch anywhere in the DNA sequence under
a hydrolysis probe decreases the overall ﬂuorescent signal
generated from that probe compared to the signal contrib-
uted by the second probe that remains fully matched
(Figure 1). Accordingly, the ratio of FAM/HEX signals
either decreases relative to the wild type or increases,
depending on whether there is a mutation under the FAM or
HEX, respectively. This principle was ﬁrst applied on a
EGFR exon 20 amplicon where the p.T790M resistance-
causing mutation lies.29
We initially used conventional PCR cycling conditions
using serial dilutions of p.T790M mutant DNA into wild-
type DNA. Under conventional cycling, the FAM-positive
versus HEX-positive droplets changed by about approxi-
mately 10-fold in the presence of 100% p.T790M mutant
sequence (Figure 3A). Serial dilutions of mutant into wild-
type indicated that the lowest mutation dilution for which
the FAM/HEX ratio is different from the wild-type samples
is 3% (P < 0.01), given the SD of the signals from three288replicates. Two-dimensional plots of the signals from
droplets following ddPCR are depicted in Supplemental
Figure S3 (one replicate of each sample). For wild-type
samples, the vast majority of droplets generate both
FAM- and HEX-positive signals, consistent with both
TaqMan probes binding efﬁciently to the target sequence.
A 100% mutant probe shifts the majority of droplets with
positive signals toward FAM, whereas reducing the mutant
abundance below 3% yields results statistically indistin-
guishable from the wild-type (t-test P > 0.01). Changing
the threshold that separates FAM/HEX-positive from
negative droplets in these two-dimensional plots changes
the absolute number of droplets within each quadrangle but
does not affect signiﬁcantly the FAM/HEX-positive ratio
or the lowest mutation abundance detectable (not shown).
By replacing conventional PCR with COLD-PCR cycling
conditions, the overall number of droplets generating signals
(positive events) for FAM and HEX are sharply reduced,
consistent with inhibition of the wild-type ampliﬁcation
(Figure 3B). Furthermore, the shift in the ratio of FAM- to
HEX-positive events is more pronounced, and the serial
dilutions indicate that approximately 0.2% mutational
abundance can be discriminated from wild type (with
approximately 1.7 higher FAM/HEX ratio) (Figure 3B).
Supplemental Figure S4 depicts two-dimensional plots of
FAM versus HEX amplitude following COLD-ddPCR for
wild-type, 5%, 1.25%, and 0.3% mutational abundance (one
replicate of each sample). The sample with 0.3% p.T790M
mutational abundance was distinguishable from that of the
wild type according to t-test with two-tailed P < 0.01. Thejmd.amjpathol.org - The Journal of Molecular Diagnostics
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Figure 4 Application of coampliﬁcation at lower denaturation
temperatureedroplet digital PCR (COLD-ddPCR) FAM/HEX ratio method for
detection of mutation p.T790M in cell-free circulating DNA samples. Serial
dilution samples were also tested in parallel to enable assessment of
mutational abundances. Numbers over the histograms indicate mutation
abundances derived via independent quantiﬁcation performed using allele-
speciﬁc ddPCR for p.T790M as described.24 The error bars represent varia-
tions among three independent detections. WT, wild type.
Figure 3 Absolute number of FAM-positive (dark gray) or HEX-positive
(light gray) events (p.T790M region) after either conventional droplet digital
PCR (ddPCR) (A) or coampliﬁcation at lower denaturation temperatureeddPCR
(COLD-ddPCR) (B). Thepresenceof thep.T790Mmismatchunder theHEX-labeled
probe during COLD-ddPCR results in an increase in the absolute number of events
for FAM, distinguishable from the wild-type sample down to mutational abun-
dances of 5% to10%or approximately 0.15% (P< 0.01) for conventional ddPCR
or COLD-ddPCR, respectively. The error bars represent maximum and minimum
number of positive events in each sample. WT, wild type.
COLD-ddPCR Enhanced Mutation Scanningsmear-like appearance is an unavoidable aspect of the
technique; however, because the method preferentially in-
hibits the ampliﬁcation of the wild-type amplicon, it does not
affect the power of discrimination of the mutant amplicon.
Experiments have been repeated multiple times, and these
smears are reproducible between replicates. Changing by
10% to 20% the threshold that separates FAM/HEX-positive
from negative droplets in these two-dimensional plots does
not affect signiﬁcantly the FAM/HEX-positive ratio (data
not shown).
Finally, to compare the ratio-of-signals method using
real-time PCR instead of ddPCR, we performed the same
experiment using real-time PCR on an ECO thermocycler
(Illumina, San Diego, CA). We calculated the FAM/HEX
ratio of ﬂuorescence signals at cycle 40, as used in ddPCR,
and also plotted the cycle threshold values for each of the
probes (FAM or HEX) (Supplemental Figure S5). The data
indicate that the lowest mutation abundance detectable via
real-time PCR is approximately 25% to 50%. In summary,
the limits of detection using the present signal ratioebased
approach with real-time PCR, ddPCR, and COLD-ddPCR
are approximately 25% to 50%, approximately 5% to
10%, and approximately 0.2% to 0.3% respectively.
cfDNA samples isolated from plasma of patients with
lung adenocarcinoma, harboring p.T790M mutations, wereThe Journal of Molecular Diagnostics - jmd.amjpathol.orgthen examined. Mutational abundances for p.T790M for
these clinical samples were independently derived using the
established ddPCR approach, with FAM- and HEX-labeled
allele-speciﬁc probes.24 Using the present approach, COLD-
ddPCR, FAM/HEX ratios from clinical samples (as an
average of three independent replicates) were distinguish-
able from the wild-type (seven independent replicates) with
the exception of PT-04-09 (Figure 4). The latter sample had
an estimated mutation abundance 0.1% using the allele-
speciﬁc ddPCR approach.
Mutation Scanning Using COLD-ddPCR for Multiple
TP53 Exon 8 Mutations
To validate the ability of COLD-ddPCR for mutation
scanning and to examine multiple mutations across an
amplicon, we developed a COLD-ddPCR assay directed to
TP53 exon 8, where cancer-relevant mutations can be pre-
sent in multiple positions. A FAM-labeled probe was
designed over the target region harboring missense muta-
tions p.R280K (MDA-MB-231) and p.R283C (HCC2218),
and a HEX-labeled probe over missense mutations p.R273H
(SW480) and p.V274F (DU-145). COLD-ddPCR experi-
ments using serial dilutions of mutational abundances for
cell lines with mutations under FAM or HEX probes, and
their corresponding ratios, are plotted in Figure 5. FAM/
HEX ratios are smaller or larger than the value of the wild
type for mutations under the FAM probe or under the HEX
probe, respectively. The lowest mutational abundance with
a FAM/HEX ratio distinguishable from wild-type DNA is
0.6% to 1.25% p.V274F (t-test with two-tailed P < 0.01).
Two clinical samples known to contain low-level TP53
mutations on exon 8 were also analyzed via COLD-ddPCR.289
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DU-145 Figure 5 Sensitivity of the coampliﬁcation at
lower denaturation temperatureedroplet digital
PCR (COLD-ddPCR) FAM/HEX ratio method for the
detection of mutations in TP53 exon 8. A and B:
FAM/HEX ratio values for serial mutant dilutions
(100%, 10%, 5%, 1.25%, 0.63%, and 0%) of
missense mutation p.R280K (located under the
FAM-labeled probe) and mutant dilutions (50%,
5%, 1.25%, 0.63%, and 0%) for p.V274F (located
under the HEX-labeled probe). C and D: FAM/HEX
ratio values for serial mutant dilutions (100%, 10%,
5%, 1.25%, 0.63%, and 0%) of missense mutation
p.R273H (located under the HEX-labeled probe) and
serial dilutions (100%, 10%, 5%, 1.25%, 0.63%,
and 0%) of p.R283C (located under the FAM-labeled
probe). The lowest distinguishable mutation
abundances in these experiments were 0.6% to
1.25% (P < 0.01). On the graph representing Taq-
man probes and DNA templates, the circles labeled
on the left side of each probe are FAM (grey) or HEX
(black). The circles labeled on the right side of
each probe are quenchers (BHQ-1). The suns
represent the release of FAM or HEX from the probe
during COLD-ddPCR. The error bars represent vari-
ations among three independent detections.
Castellanos-Rizaldos et alA colorectal cancer (CT20), containing a missense mutation
p.R273H is depicted in Figure 6A. FAM/HEX ratio values
for CT20 (1.54:1) were similar to those obtained for
approximately 1% mutant abundance (1.58:1), in agreement
with previous ﬁndings.23 And a plasma-cfDNA sample
obtained from a radiation therapy patient containing a TP53
mutation (p.R283C) is depicted in Figure 6B. FAM/HEX
values indicate that the estimated mutation abundance in
that particular sample (as an average of six replicates) was
about approximately 5%, in agreement with previous ﬁnd-
ings.23,30 Corresponding two-dimensional plots depicting
signals from droplets following ddPCR are shown in
Figure 6C. During COLD-ddPCR, cfDNA samples con-
taining mutations are preferentially ampliﬁed, whereas the
wild-type amplicon is inhibited. When the mutation over-
laps the HEX probe, the FAM signal is increased (CT20),290whereas the opposite occurs when the mutation overlaps the
FAM probe (as in sample FC39-4).
Discussion
Sequencing remains the gold standard for identifying un-
known DNA mutations, especially at the present time,
when throughput and sensitivity issues for next-generation
sequencing are gradually being addressed.31e33 Never-
theless, sequencing remains a relatively expensive option
when a limited group of targets needs to be examined.
Mutation scanning is an attractive alternative that balances
well resources versus the information obtained.34 There are
several methods for mutation scanning using PCR-based
technology, including high-resolution melting,13,35 which
provides the ability to rapidly pre-screen samples beforeFigure 6 Detection of mutations in solid
tumor and cell-free circulating DNA (cfDNA) sam-
ples by the coampliﬁcation at lower denaturation
temperatureedroplet digital PCR (COLD-ddPCR)
FAM/HEX ratio method in TP53 exon 8. A: FAM/HEX
ratio value for clinical sample CT20, harboring
missense mutation p.R273H (overlapping the HEX-
labeled probe). B: FAM/HEX ratio for a cfDNA
sample, FC39-4 with the missense mutation
p.R283C (overlapping the FAM-labeled probe). C:
Two-dimensional plots for CT20 and FC39-4 sam-
ples obtained following COLD-ddPCR. The error
bars represent variations among three indepen-
dent detections. Ch1/2, channel 1/2.
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COLD-ddPCR Enhanced Mutation Scanningsequencing.34 However, high-resolution melting cannot be
performed on individual droplets, thus it has not been
possible to combine high-resolution melting with ddPCR
technology for mutation scanning. Because ddPCR is
becoming widely used now that commercial platforms are
available, a mutation scanning approach based on ddPCR
is timely.
COLD-ddPCR is a novel combination of COLD-PCR
and ddPCR technologies that enables mutation scanning
over a target region as opposed to allele-speciﬁc ddPCR,
which interrogates a single nucleotide. COLD-PCR cycling
inhibits ampliﬁcation of the wild-type amplicon. This inhi-
bition reduces wild-type background signals and improves
the limit for mutation detection.9
COLD-PCR suppresses wild-type DNA ampliﬁcation for
amplicons up to 200-bp long.21 As applied here, COLD-
ddPCR interrogates the region covered by the two hydro-
lysis probes, ie, an approximately 50-bp region here. To
interrogate additional sections of the amplicon, a second
reaction addressing different regions could be performed.
Alternatively, three or more hydrolysis probes labeled with
different ﬂuorophores could be used simultaneously, whose
relative signal ratios would inform about the presence of a
mutation. Although the present application used the simplest
form of COLD-PCR (fast-COLD-PCR), COLD-ddPCR
may potentially also be applicable with other forms of
COLD-PCR, full-PCR16,36 or ICE-COLD-PCR,20,37 which
enrich for all possible mutations within an amplicon.
A question pertains to how the COLD-ddPCR ratio
method behaves in the simultaneous presence of two mu-
tations on the same DNA molecule. The probability that
there will be two neighboring mutations on the same DNA
molecule (ie, not on different alleles or different tumor
clones) is low, but not negligible. If the two mutations lie
under the same TaqMan probe, then the ratio method will
still be effective. If the mutations lie under different TaqMan
probes, there could be a problem in their detection. How-
ever, during fast-COLD-ddPCR, the binding of the two
TaqMan probes will likely be affected to a different extent
from each of the two mutations, hence, still resulting in an
altered signal ratio.
In summary we presented a process using a combination of
COLD-PCR and digital PCR technologies that enables
droplet-digital PCR to identify multiple mutations and
potentially perform mutation scanning of short target regions
by observing shifts to the ratio of ﬂuorescent signals from two
probes. This approach, enhanced ratio of signals for mutation
scanning COLD-ddPCR, is able to scan for low-level muta-
tions, with a limit of detection of approximately 0.2% to 0.6%
mutant-to-wild-type ratio.
This method can be applied to clinical samples where mul-
tiple mutations along an amplicon can have clinical signiﬁ-
cance, such as TP53, codons 12 and G13 of KRAS (v-Ki-ras2
Kirsten rat sarcoma viral oncogene homolog), or mutations
around V600E in BRAF (v-Raf murine sarcoma viral oncogene
homolog B1) in cfDNA, urine, or other clinical samples whereThe Journal of Molecular Diagnostics - jmd.amjpathol.orgmutations can serve as biomarkers for prognostic, predictive, or
therapy monitoring purposes.
Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.jmoldx.2014.12.003.
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